Physician profile
John E Hetlinger
NPI 1457373524
$6,800.53
in general payments reported to CMS, 2019-2025
52 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $813 · 2021: $1,118 · 2022: $1,428 · 2023: $809 · 2024: $996 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma INC | $976.00 | 2022 | |
| Abbvie INC. | $914.04 | 2020-2025 | |
| Amgen INC. | $580.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $356.01 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $316.79 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $286.23 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.76 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.42 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $225.44 | 2020-2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $199.04 | 2023-2025 | Auvelity |
| Pfizer INC. | $177.04 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $170.01 | 2019-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $155.26 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $148.47 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $145.22 | 2019-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hetlinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.